Patient-reported outcomes (PROs) refers to reports directly obtained from patients about their health status, physical function and treatment experience, which has been widely used in evaluation of quality of life in chronic diseases, clinical trials, adverse event monitoring and drug registration and approval in recent years. Rare diseases are a kind of diseases that seriously affect the physical function, mental health and quality of life of patients. Due to the lack of understanding of the natural history of rare diseases and the lack of sensitive biomarkers, patients' opinions and feelings are the key and ultimate goal of clinical decision making and intervention efficacy evaluation for rare diseases. At present, domestic research on PROs is just starting, and few involves in rare diseases. Therefore, this article reviewed the international definition, policy history and application status of PRO in rare diseases, and further discussed the existing challenges in the application of PRO in rare diseases, and looked forward to the application prospects of PRO in China.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |